ASH 2023 | BCL2 inhibition with sonrotoclax for treating t(11;14) multiple myeloma
Susan Bal, MD, MBBS, University of Alabama at Birmingham, Birmingham, AL, discusses the use of sonrotoclax, a potent oral BCL2 inhibitor, as a personalized approach to treating t(11;14) multiple myeloma (MM). Despite disappointing outcomes in the CANOVA trial (NCT03539744) for BCL2 inhibition in this patient population, sonrotoclax emerges as an efficacious and well-tolerated treatment option. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies
Honoraria: BMS, AbbVie, Janssen, Astrazeneca, Adaptive Biotechnologies, MJH Life Sciences
Research Funding: BMS, Adaptive Biotechnologies, Amyloid Foundation, BeiGene, Fate Therapeutics
Educational Content Development: MJH Life Sciences
